ABBV · News · 20260911N

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-09-11 · Importance 31 · Surprise 42

AbbVie reported positive top-line Phase III LUNA results for atogepant, an oral calcitonin gene-related peptide receptor antagonist. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in migraine days versus placebo for preventive treatment of menstrual migraine. The results could expand the commercial opportunity for AbbVie’s Qulipta/Aquipta migraine franchise, which is already approved for migraine prevention, into a condition with no specifically approved treatment.

Key facts

• AbbVie announced positive Phase 3 trial results for its menstrual migraine treatment, atogepant, in an announcement that preceded share movement on Friday morning. source
• AbbVie announced positive top-line data from its Phase III LUNA study for atogepant, an oral calcitonin gene-related peptide receptor antagonist, for the preventive treatment of menstrual migraine. source
• The Phase III LUNA study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in migraine days compared to placebo. source
• The LUNA study data could expand the commercial opportunity for AbbVie's Qulipta/Aquipta, which is already approved for migraine prevention. source
• AbbVie's announcement noted there is no specific treatment approved for menstrual migraine. source